|Table of Contents|

The effect of Morphine combined with Erlotinib on proliferation and apoptosis of human lung adenocarcinoma cancer HCC827 cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 06
Page:
828-830
Research Field:
Publishing date:

Info

Title:
The effect of Morphine combined with Erlotinib on proliferation and apoptosis of human lung adenocarcinoma cancer HCC827 cells
Author(s):
Zhang Yajing; Zhang Zhenping; Hou Yuehong; Xiang Cheng; Zhang Yan
Department of Oncology,Shijiazhuang First Hospital,Hebei Shijiazhuang 050000,China.
Keywords:
non-small cell lung cancer; Erlotinib; Morphine; apoptosis
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2018.06.004
Abstract:
Objective:To investigate the effect of Morphine combined with Erlotinib on the proliferation and apoptosis rate of HCC287 cell lines.Methods:MTT method was used to observe the proliferation rate at 48 h after the treatment of Morphine at different concentrations(250,500,1 000 μmol/L) and Erlotinib(10,20,40 μmol/L).Flow cytometry was used to detect the apoptosis rate after 24 h treatment in control,Morphine,Erlotinib and Morphine+Erlotinib group.Results:Compared to the control group,the proliferation rate of HCC827 cells was decreased in the Morphine and Erlotinib group,the apoptosis rate was increased in the Morphine,Erlotinib and Morphine+Erlotinib group.Conclusion:High-dose Morphine has a synergistic effect with Erlotinib hydrochloride in anti-tumor activity,which may be closely related to apoptosis.

References:

［1］ Parums DV.Current status of targeted therapy in non-small cell lung cancer［J］.Drugs Today(Barc),2014,50(7):503-525.
［2］ Burotto M,Manasanch EE,Wilkerson J,et al.Gefitinib and erlotinib in metastatic non-small cell lung cancer:A Meta-analysis of toxicity and efficacy of randomized clinical trials［J］.Oncologist,2015,20(4):400-410.
［3］ Xu JL,Jin B,Ren ZH,et al.Chemotherapy plus erlotinib versus chemotherapy alone for treating advanced non-small cell lung cancer:A Meta-analysis［J］.PLoS One,2015,10(7):e0131278.
［4］Brokjar A,Kreilgaard M,Olesen AE,et al.Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration—a dose escalation study［J］.Eur J Pharm Sci,2015,68:78-86.
［5］Ku BM,Sun JM,Lee SH,et al.An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer［J］.Expert Rev Mol Diagn,2017,17(10):933-942.
［6］ Reckamp KL.Advances in immunotherapy for non-small cell lung cancer［J］.Clin Adv Hematol Oncol,2015,13(12):847-853.
［7］ Ghaly G,Rahouma M,Kamel MK,et al.Clinical predictors of nodal metastases in peripherally clinical T1aN0 non-small cell lung cancer［J］.Ann Thorac Surg,2017,104(4):1153-1158.
［8］ Guohua H,Hongyang L,Zhiming J,et al.Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs［J］.Biosens Bioelectron,2017,97:184-195.
［9］ Sekar A,Gupta N,Rajwanshi A,et al.The role of the cytopathologist in subtyping and epidermal growth factor receptor testing in non-small cell lung cancer:An institutional experience［J］.Cytopathology,2017,28(5):371-377.
［10］Panicker PS,Melge AR,Biswas L,et al.Epidermal growth factor receptor(EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations［J］.Chem Biol Drug Des,2017,90(4):629-636.
［11］ Yeo WL,Riely GJ,Yeap BY,et al.Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations［J］.J Thorac Oncol,2010,5(7):1048-1053.
［12］ Lelj-Garolla B,Kumano M,Beraldi E,et al.Hsp27 inhibition with OGX-427 sensitizes non-small cell lung cancer cells to erlotinib and chemotherapy［J］.Mol Cancer Ther,2015,14(5):1107-1116.
［13］ Fujioka N,Nguyen J,Chen C,et al.Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer［J］.Anesth Analg,2011,113(6):1353-1364.
［14］ Lennon FE,Mirzapoiazova T,Mambetsariev B,et al.The Mu opioid receptor promotes opioid and growth factor-induced proliferation,migration and epithelial mesenchymal transition(EMT) in human lung cancer［J］.PLoS One,2014,9(3):e91577.
［15］Hatsukari I,Hitosugi N,Matsumoto I,et al.Induction of early apoptosis marker by morphine in human lung and breast carcinoma cell lines［J］.Anticancer Res,2003,23(3B):2413-2417.
［16］ Hatsukari I,Hitosugi N,Ohno R,et al.Induction of apoptosis by morphine in human tumor cell lines in vitro［J］.Anticancer Res,2007,27(2):857-864.
［17］Suenaga M,Yamamoto M,Tabata S,et al.Influence of gefitinib and erlotinib on apoptosis and c-MYC expression in H23 lung cancer cells［J］.Anticancer Res,2013,33(4):1547-1554.
［18］Steins M,Thomas M,Geissler M.Erlotinib［J］.Recent Results Cancer Res,2014,201:109-123.

Memo

Memo:
河北省科技计划项目(编号：15277127)
Last Update: 2018-01-29